-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1482 Subtypes and Treatment Outcomes of Adolescent and Adult Non-Hodgkins Lymphoma in a Resource Poor Setting

Non-Hodgkin Lymphoma: Biology, excluding Therapy
Program: Oral and Poster Abstracts
Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster I
Saturday, December 5, 2015, 5:30 PM-7:30 PM
Hall A, Level 2 (Orange County Convention Center)

Yvonne Akotoa Dei-Adomakoh, MBBS1*, Eugenia Quartey, MBChB2*, Catherine Idara Segbefia, MBChB3*, Elsie Amedonu, BSc1*, Afua Abrahams, MBChB1* and Joseph Acquaye, MBBS1*

1University of Ghana, School of Biomedical and Allied Health Sciences, Accra, Ghana
2Korle Bu Teaching Hospital,Accra,Ghana, Accra, Ghana
3University of Ghana, School of Medicine and Dentistry, Accra, Ghana

Introduction: Non- Hodgkins lymphomas (NHL) are a heterogeneous group of clonal malignant diseases arising from the lymphoid system with many subtypes showing both biological and clinical heterogeneity. However, the diagnosis and treatment outcomes of NHL in resource poor countries still remain a challenge in the absence of routine immunohistochemistry and molecular studies. In Ghana, a low middle-income West African country, there has been no previous systematic study of the distribution of the major subtypes of NHL.

Methods: A retrospective review of case folders of all patients age 13 years and above, diagnosed with NHL between January 1, 2008 and October 31, 2013, at Korle Bu Teaching Hospital (KBTH), Accra, the largest hospital in Ghana, and one of only two hospitals in the country with a cancer unit. Information obtained from the case folders included age, sex, histological subtype, subtypes using the Working Formulation and WHO classifications. Treatment given and follow up information were also evaluated.

Results: A total of 279 cases of NHL were identified within the study period. The mean overall age of the patients was 48.8 ± 17.0 years with a minimum age of 13 years and maximum 87 years. There were 156 males (55.7 %) and 123 females (43.9 %) with a male to female ratio of approximately 1.5:1. The majority of cases seen (53%) were diffuse large B- cell lymphoma. Chronic lymphocytic leukaemia/ small lymphocytic lymphoma (22.2%) was the next commonest subtype. Other sub types seen, in order of frequency, included diffuse mixed cell lymphoma (6.4%), gastric lymphomas (3.9%), mediastinal B- cell lymphoma (2.9%), Burkitts lymphoma (1.8%), splenic marginal zone B-cell lymphoma (1.1%), lymphoblastic lymphoma (1.1%), mucosa- associated lymphoid tissue (MALT) type B- cell lymphoma (0.7%) and follicular lymphoma (0.7%). Others, which included anaplastic large cell lymphoma, mantle cell lymphoma, lymphoplasmacytic lymphoma and mycosis fungoides, collectively accounted for 3.6% of the NHL cases reviewed. Based on the Working Formulation classification with broad histologic categories of low-, intermediate-, and high-grade lymphomas, 83 out of 279 (29.7%) had low grade NHL, 170 (60.7%) intermediate and 26(9.4%) had aggressive/high grade NHL.

Table 1 shows chemotherapy regimens administered and first year treatment outcomes. One-year survival for cases of NHL in the study was found to be high (98.6%). However, only 115/279(41.2%) of patients were seen for follow up in the second year post-treatment, with 85 of these (73.9%) still in clinical remission. In the third year only 37/279(13.3%) reported for follow up.

Conclusions: This study provides a baseline overview of the distribution of NHL subtypes and their outcomes in adolescent and adult patients in a resource constrained setting. Patient loss to follow up in the 2nd and 3rd year post treatment was very high and the reasons for this should be explored in a future study. Immunohistochemistry, cytogenetics and specific molecular studies, which are important in characterization of NHL, should be made affordable and accessible in low-income countries.

TABLE 1: FIRST YEAR OUTCOME FOR ALL NHL SUBTYPES AND TREATMENT GIVEN

TYPE OF CHEMOTHERAPY GIVEN

CHOP

CVP

R-CHOP

CHLORAMBUCIL + PREDNISOLONE

CODOX-M/ IVAC

TOTAL

INDOLENT TYPE NHL

CR

37

34

2

2

0

75 (26.9%)

PR

3

1

0

0

0

4 (1.4%)

NR

1

0

0

0

0

1 (0.4%)

LTF

2

0

0

0

0

2 (0.7%)

TOTAL

43 (15.5%)

35 (12.5%)

2 (0.7%)

2 (0.7%)

0 (0.0%)

82(29.4%)

INTERMEDIATE TYPE NHL

CR

120

3

9

0

0

132 (47.3%)

PR

32

4

0

0

0

36 (12.9%)

NR

1

0

0

0

0

1 (0.4%)

LTF

2

0

0

0

0

2 (0.7%)

TOTAL

155 (55.6%)

7 (2.5%)

9 (3.2%)

0 (0.0%)

0 (0.0%)

171 (61.3%)

AGGRESSIVE TYPE NHL

CR

9

0

3

0

1

13 (4.65%)

PR

12

0

0

0

1

13 (4.65%)

NR

0

0

0

0

0

0 (0.0%)

LTF

0

0

0

0

0

0 (0.0%)

TOTAL

21 (7.5%)

0 (0.0%)

3 (1.1%)

0 (0.0%)

2 (0.7%)

26 (9.3%)

GRAND TOTAL

219 (78.5%)

42 (15.1%)

14 (5.0%)

2 (0.7%)

2 (0.7%)

279 (100%)

CR: CLINICAL REMISSION, PR: POOR RESPONSE, NR: NO RESPONSE, LTF: LOST TO FOLLOW- UP

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH